Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Next Wave Ventures in connection with the acquisition of Rexam Plc’s Petainer operations
Mandate

Vinge advises Next Wave Ventures in connection with the acquisition of Rexam Plc’s Petainer operations

November 23, 2009

Vinge has advised Next Wave Ventures in the acquisition by Next Waves and WHEB Ventures of Rexam Plc’s Petainer operations in Sweden, the Czech Republic and Germany for approximately SEK 190,000,000 (GBP 16,000,000).

Rexam’s Petainer operations manufacture PET beverage containers. The facilities in Lidköping and the Czech Republic have 250 employees and a combined turnover of SEK 700 million. These facilities primarily supply PET bottles to the Nordic and German markets. Next Wave is an English private equity and venture capital firm focused on investing in UK and European small cap companies and WHEB invests in companies focusing on environmentally friendly technology and sustainable solutions.

The Vinge team advising Next Wave consisted of partner Jesper Ottergren together with, among others, associates Anna Bjering, Magnus Bigner, Anna Bergstrand, Susanne Samuelsson and Ida Christensson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024